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Abstract
Epithelial–myoepithelial carcinoma (EMC) is a rare subtype of salivary gland neoplasms. Since the initial description of the cancer,
just over 300 cases have been reported. EMCs occupy a biphasic cellular differentiation-state defined by the constitution of two cell
types representing epithelial and myoepithelial lineages, yet the functional consequence of the differentiation-state heterogeneity with
respect to therapy resistance of the tumors remains unclear. The reported local recurrence rate of the cases is approximately 30%, and
while distant metastases are rare, a significant fraction of these cases are reported to receive no survival benefit from radio- or
chemotherapy given in addition to surgery. Moreover, no targeted therapies have been reported for these neoplasms. We report here
the first use and application of ex vivo drug screening together with next generation sequencing to assess targeted treatment strategies
for a rare metastatic epithelial–myoepithelial carcinoma. Results of the ex vivo drug screen demonstrate significant differential ther-
apeutic sensitivity between the epithelial and myoepithelial intra-tumor cell lineages suggesting that differentiation-state heterogene-
ity within epithelial–myoepithelial carcinomas may present an outlet to partial therapeutic responses to targeted therapies including
MEK and mTOR inhibitors. These results suggest that the intra-tumor lineage composition of EMC could be an important factor to
be assessed when novel treatments are being evaluated for management of metastatic EMC.
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Introduction
Epithelial–myoepithelial carcinoma (EMC) of the salivary gland is a
rare type of cancer that account for 0.4 to 1.5% of all salivary gland
tumors. Initial pathological description of EMC was published in 1972
[1], and the largest worldwide review of cases has covered 246 cases [2].
Altogether some 350 cases of EMC have been reported in the literature.
The tumorigenesis of these rare cancers is largely unclear, but the single
common feature of the cancer is the histological biphasic morphology
composed of epithelial and myoepithelial cell lineages defining the key his-
tologic characteristic finding used in the diagnosis of EMC (Fig. 1A).
Clinically, local EMC has been described as a low-grade neoplasm that
progresses slowly. The tumors are most commonly arising from the paro-
tid glands and to lesser extent from submandibular or minor salivary
glands. Histologically the EMC neoplasms consists of both epithelial
and myoepithelial cells arranged in differentiated ductal tubules, trabecu-
lae, small islands or sheets with varying differentiations, but commonly no
or little invasion to surrounding tissues. Although the reported local recur-
rence rate of EMC is up to 30–40% [2,3], mortality of EMC is low [2,4],
despite for the rare metastatic disease to which no curative treatment is
available [2,5]. The mainstay of treatment of EMC carcinomas consists
of surgery with up to 97% of patients described in literature going through
surgery [2]. Due to the low number of cases, no large randomized trials
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have been performed for EMC and the role of e.g. adjuvant radiotherapy
and chemotherapy after surgery is not clearly defined. Thus, systemic ther-
apy for recurrent and/or metastatic EMC is generally based on standard
cytotoxic drugs such as doxorubicin, cisplatin, 5-fluorouracil, paclitaxel
and navelbine [6–8]. Given the rarity of metastatic EMC tumors and
the variability in nature of the metastatic disease, the survival benefits of
cytotoxic agents in treatment of EMC has not been defined and the
reported clinical responses have been short in duration. Therefore, there
is a need for better understanding of the complex biology of epithelial–
myoepithelial carcinoma, and to develop therapeutic approaches consider-
ing the cellular heterogeneity of the tumors and the underlying genetic
background such as the frequent association of EMC with Harvey rat sar-
coma viral oncogene homolog (HRAS) mutations [9–11].
In this study, we report the first use of ex vivo analysis of drug sensitiv-
ity for a rare metastatic EMC case to inform the treatment of the patient
after the standard treatments had been exhausted. Use of high-throughput
ex vivo drug screening [12–14] is an attractive application for biomarker
discovery and assessment of patient specific therapy sensitivity especially
for rare cancers for which large-scale clinical trials of novel therapies are
challenging due to low number of cases [15]. To assess sensitivity of the
patient derived EMC cells to targeted cancer therapeutics, we present
the utility of a pathological marker informed high-content assay (HCA)
strategy to track epithelial and myoepithelial sub-cell populations through
immunofluorescent markers in an ex vivo -high content drug screen. Our
findings elucidate how EMC tumor derived cells with pronounced
differentiation-state heterogeneity respond to specific targeted pathway
antagonism at single cell resolution, revealing dramatic differentiation state
selectivity for pathway-targeted drugs. Using these methods to understand
how pharmacologic pathway antagonism affects the intra-tumoral hetero-
geneity in EMC, we may begin to predict the phenotypic responses of
patients¨ tumor cells to therapy in vivo, and thus design drug combina-
tions and new indications for currently existing targeted cancer therapeu-
tics to treat metastatic EMC.
Materials and methods
Patient
The patient, a 36-year old female, was identified to the study by an oncol-
ogist at the Tampere University Hospital (Tampere, Finland). The patient
was initially diagnosed at age of 32 when radical surgery of the salivary gland
was performed. Diagnosis was myoepithelial–epithelial carcinoma of the
salivary gland. Whole-body CT (computerized tomography) scan indicated
no distant disease spread and patient was considered cured of the disease and
she received no additional adjuvant treatment. At age of 36 the patient was
diagnosed with multiple small metastatic disease nodules in the right lung
and two large intrapulmonary metastatic lesions which were biopsied to
obtain diagnosis. Tissue morphology was similar to the primary tumor
(Fig. 1A). Metastases were inoperable and patient was referred for systemic
Fig. 1. Histological comparison of the patient's primary tumor, the lung metastasis and cell culture. (A) Immunofluorescent staining of KRT19 (red) and
KRT14 (green) in the patient¨s primary tumor and the lung metastasis tissue. DNA shown in blue. Bars 50 mm. (B) Two 18-gauge needle biopsy cores
were used to establish an ex vivo cell culture for the drug screening. Bar 1 mm. (C) Immunofluorescent staining of KRT19 (red), KRT14 (green) and
Vimentin (blue) in the ex vivo tumor cell culture. Bar 50 mm.
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therapy. First line chemotherapy consisted of cisplatin, docetaxel and 5-
fluorouracil. Clinically, she did not benefit from the treatment and objective
response evaluation with whole-body CT imaging after three cycles indi-
cated clear disease progression. The patient was then considered for detailed
molecular pathology profiling and the ex vivo therapy sensitivity study. Nee-
dle biopsy samples were collected for the ex vivo drug screening and DNA
sequencing with approval from the local Ethics Committee of the Central
Finland Health Care District (KSSHP 3U/2015). All the experiments were
undertaken with the understanding and written informed consent of the
patient and the study methodologies conformed to the standards set by
the Declaration of Helsinki.
Tissue specimens
FFPE histological specimens from the patient's primary tumor were
available for the study from the time of initial diagnosis and surgical resec-
tion of the tumor with clinical follow-up data available. Four 18-gauge
coarse needle biopsy cores from metastatic lesion in the right lung were
collected for the next generation sequencing and ex vivo drug screening
experiments.
Tumor derived primary cell culture
Two of the four 18-gauge coarse needle biopsy cores sampled from the
metastatic lesion were devoted to establish a vital cell culture from the
patient's tumor cells. The tissue cores were placed in sterile RMPI-1640
medium (Gibco) without supplements for transport to the research labora-
tory (Fig. 1B). One needle core was fixed in 4% buffered formaldehyde,
paraffin-embedded, cut at 4 lm, and subjected to routine histological stain-
ing procedures as well as fluorescence immunocytochemistry (Fig. 1A).
Immediately upon receipt, the live tissue samples were washed three times
with sterile PBS and finely cut to 2–5 mm [3] pieces in sterile cell culture
medium using scalpels. The primary bulk cell suspension dissociated from
the tumor tissue during cutting was collected into a sterile centrifuge tube.
The remaining tissue fractions where then placed into 1 mL of Accutase cell
dissociation reagent (Gibco) per tissue and incubated at room temperature
for 60 minutes. Following the enzymatic dissociation, the resulting cell sus-
pensions and the initial cell suspension from the tissue cutting plates were
combined, collected with centrifugation and subjected to filtration through
a 70 mm cell strainer (pluriSelect Life Science UG) in sterile RMPI-1640
medium. The resulting cell suspension was quantified using a Cellometer
Mini cell counter (Nexcelom). In total 2.5  10^6 cells with an average size
of >13 mmwas derived from the tumor tissue. The suspension was diluted to
RPMI-1640medium containing 5%FBS to achieve a suspensionwith 1000
cells per 45 mL of medium. 10^6 cells were used for the initial ex vivo drug
screening and the rest were placed to cell culture in standard cell culture con-
ditions (37 C, 5%CO2). Following four days in culture, the cells presented
an adherent phenotype with distinct sub-cell populations representing the
tumor tissue (Fig. 1C).
Mutation analysis
The genomic profiling was purchased as a service from the Finnish
Institute for Molecular Medicine (FIMM) Genomic Core (Helsinki, Fin-
land). Briefly, genomic DNA was isolated from two fresh 18-gauge coarse
needle biopsy cores using the Epicentre Master pure DNA and RNA iso-
lation kit (Illumina) according to the manufacturer's protocol. Germline
DNA was obtained from a non-cancerous skin biopsy. Exome capture
was performed using Nextera Rapid Capture Exome Kit (Illumina).
Sequencing libraries were sequenced using paired end 100 bp read format
on an Illumina HiSeq2500 instrument (Illumina). Result of the mutation
analysis are provided in the Supplementary Data 1.
Immunostaining of tissue samples
The primary and metastatic tumor tissue samples were formalin-fixed,
paraffin-embedded and cut sections were prepared with pathologist assis-
tance. For immunofluorescence staining 5 mm cut sections were de-
paraffinized in xylene and passed through a series of graded alcohols. Anti-
gen retrieval was performed in a 0.1 M sodium citrate buffer pH 6 (Sigma)
under heat and pressure, followed by blocking with a 1% BSA (Thermo-
Fisher) blocking buffer. Sections were incubated overnight at 4 C with a
primary antibody solution with epithelial marker cytokeratin-19 (KRT19,
Dako, Clone RCK108), 1:300), myoepithelial marker cytokeratin-14
(KRT14, Abcam, Clone LL002, 1:300) and proliferating cell marker
Ki-67 (DAKO, Clone MIB-1, 1:200) diluted in 1% BSA. Sections were
washed in PBS with 0.1% Tween (ThermoFisher) and secondary antibody
staining was performed at room temperature for 1 hour with AlexaFluor
secondary antibodies against primary host species (1:500, LifeTech) in
1% BSA. 1 lg/ml DAPI (40,6-Diamidino-2-phenylindole nuclear coun-
terstain, LifeTech) was added to secondary staining buffers. Tissue sections
were imaged on an Olympus scan^R platform at 20 magnification.
Image-based drug screening
The therapeutic compound collection used in the ex vivo study con-
sisted of 134 FDA approved anti-cancer agents, along with 12 investiga-
tional compounds covering key cancer associated signaling pathway
targets (Supplementary data 2). The compounds were purchased from
commercial chemical vendor (Selleck biochemicals) readily dissolved in
dimethyl sulfoxide (DMSO). Platinum based compounds were dissolved
in water. The ex vivo drug screening was performed in tissue culture trea-
ted 384-well microplates (Corning CellBIND, #3770). Each compound
was tested in four different concentrations with 2-fold dilutions starting
from 5 micromolar as the highest. A single-cell suspension of freshly iso-
lated tumor cells (45 ml per well; 1000 cells per well) was transferred to
each well using a peristaltic dispenser (ThermoScientific). The 384-well
plates were incubated for 96 h at standard cell culture conditions. Analysis
of cell viability with cellular lineage separation was performed through
high-content imaging. The cell cultures were fixed and stained as detailed
above (Immunostaining of tissue samples) with antibodies against epithe-
lial KRT19 (1:300), myoepithelial KRT14 (1:300) and DAPI for DNA
counterstaining. Cells were imaged on the Olympus scan^R platform at
10 magnification. 6 frames were acquired from each 384-well. Images
were analyzed with Olympus scan^R image analysis suite including
DNA staining-based primary object segmentation using a watershed algo-
rithm. Primary objects (nuclei) were expanded a fixed 10-pixel distance,
and mean fluorescence signal intensity for KRT19 and KRT14 was quan-
tified from this expanded cellular region. Single cell positivity for KRT19
and KRT14 were determined by gating in the scan^R image analysis suite,
using cells negative for each marker as controls. Population separated cell
count data was normalized to DMSO-only wells (negative control), 5 mM
staurosporin-containing wells (positive control) and 2 mM aphidicolin-
containing wells (cell growth control). Dose response curves for growth
rate normalized GR50, IC50, maximal inhibition (Emax) and the pro-
jected maximal inhibition (Einf) estimates were generated in GraphPad
Prism software (V7, GraphPad Software Inc.).
Statistical analysis
The ex vivo drug screening data was analyzed using the normalized
growth rate inhibition (GR) approach which yields per-division metrics
for drug potency (GR50) and efficacy (GRmax). The normalized growth
rate inhibition (GR) method corrects for variation in division rates by esti-
mating the magnitude of drug response on a per cell-division basis
392 Ex vivo assessment of targeted therapies in a rare metastatic R. MÌkelÌ et al. Neoplasia Vol. 22, No. 9, 2020
[13,14]. For analysis of variation in cell lineage heterogeneity following
drug treatments we used the Shannon diversity index as a metric of cell-
state heterogeneity. Cell state frequencies were calculated using the Olym-
pus scan^R imaging cytometry software (Olympus OSIS, Germany) as
described above. For each drug treatment, the proportion of each cell state
(Pi) was calculated by dividing cell state number by the total cell number
in the well. The Shannon diversity index (H0) was then calculated by mul-
tiplying Pi by the log2 of Pi, for each cell state, then summing these num-
bers for the total number of states (S).
H A^ ¼
X2
i¼1
P i lnP i
Combination indices (CI) were calculated from replicate, fixed-ratio,
dose escalation experiments using the Chou and Talalay method [17].
CI values were reported at 50% inhibitory values (CI50). Welch's t-test
and Pearson correlation analyses were applied using GraphPad Prism V7
software as indicated in the figure legends according to assumptions on
data normality.
Results and discussion
Image-based ex vivo drug efficacy screening
The patient was initially treated with radical surgery of the affected sali-
vary gland. Adjuvant treatment of the patient following metastatic relapse
consisted of three cycles of chemotherapy with cisplatin, docetaxel and 5-
fluorouracil. The disease progressed immediately through the adjuvant
chemotherapy. At this stage, coarse needle tumor biopsies were received
for the purpose of genetic profiling and ex vivo therapy efficacy screening.
For the ex vivo drug screening experiment the tissue samples were pro-
cessed immediately on the day of biopsy. Using standard techniques to
establish primary cell cultures from human tissues [18], a primary culture
was prepared from the patient's tumor tissue. This bulk tumor cell sample
was then used for a high content drug screen to assess the relative lineage
specific cytotoxicity of 146 drugs representing various anti-cancer drug
classes with a fixed dose range (Supplement data 2). Cells were exposed
to the drugs for 96 h and automated microscopy and image analysis were
used to quantify cell growth on basis of cell counting following staining
with lineage specific intermediate filament markers KRT19 and KRT14
(Fig. 1A). Aphidicolin was used as a reference molecule to monitor and
normalize the dose responses with respect to growth rate (GR) during
the assay. With comparison of the negative control samples (DMSO only)
and aphidicolin treated cells, the estimated cell doubling rate of all the
tumor tissue derived cells was calculated to be 34 h corresponding [19]
(Fig. 2A). 70% of the cells in control conditions were positive for the
epithelial lineage marker KRT19. Cell division rate of the KRT19+ cells
was calculated to be 24 h corresponding to 4 cell division over the course
of the assay. 17% of the cells were positive for the myoepithelial lineage
marker KRT14. Cell division rate of the KRT14+ cells was calculated to be
56 h (Fig. 2A). The differential proliferation rate of the two different cell
lineages reflected the population specific Ki67 index in the lung metastasis
tissue where the measured Ki67 index of KRT19+ cells was 19% and 12%
for KRT14+ cells (Supplement Fig. 1A). To identify the most potent
growth inhibitory drugs, we compared the GR values of the drugs calcu-
lated separately for the KRT19+ cells, KRT14+ cells and all cells (Fig. 2B,
Supplement Fig. 2). The GR metrics were combined with analysis of
changes in the diversity of proportional lineage heterogeneity measured
using a Shannon diversity index score [16] to identify lineage specificity
in the drug efficacy (Fig. 2B). Using a stringent ranking criterion where
the average of the GR values across all four drug doses had to be stronger
than GR = 0 (the cell growth stalling effect of aphidicolin), we identified
21 drugs associated with strong a cytotoxicity effect on all the cells, 30
drugs with strong cytotoxicity on the KRT19+ cells and 36 drugs with
strong cytotoxicity on the KRT14+ cells (Supplement Fig. 3). The overall
drug efficacy results (IC50) of all the drugs correlated best between the fas-
ter proliferating KRT19+ cells and analysis of all the cells (Pearson corre-
lation r = 0.98). The correlation of the IC50 results between KRT19+ and
KRT14+ cells displayed significant variation for selected drugs enriched for
mTOR, MEK, HDAC and DHFR (dihydrofolate reductase) inhibitors
(r = 0.86) (Fig. 2C, Supplement Fig. 2). To identify the drugs with most
differential efficacy between the two cell lineages, we performed a pair-
wised correlation analysis of the growth rate normalized dose responses
of the KRT19+ and KRT14+ cells. From the pathway targeted therapeu-
tics, the GR dose response profiles of drugs against mTOR, MEK, Bcr-
Abl, HDAC, PDGFR and Raf had a strong negative correlation between
the two cell lineages (r < 0.5) reflecting differential growth inhibitory
efficacy dependent on the lineage state (Fig. 2D). From this list of drugs,
the GR dose response difference was statistically most significant (Welch's
t test) for MEK inhibitor AZD6244 (Selumetinib), Raf inhibitor AZ628,
HDAC inhibitor Vorinostat, MEK inhibitor Trametinib, mTOR inhibi-
tor Temsirolimus and mTOR inhibitor AZD8055 (Fig. 2E).
Analysis of lineage selective growth inhibition
The microscopy-based assay strategy allows detailed analysis of changes
in total cell numbers, cell cycle distribution, and sub-cell lineage marker
identified population dynamics at single-cell resolution. The multiparam-
eter data can thus be used to discover and assess drug induced changes
through multiple phenotypes. As an example, drug induced effects on cell
cycle distribution can be analyzed with imaging cytometry [20] and used
to group drugs and drug classes according to cell cycle arresting features
(Supplement Fig. 4). With analysis of the epithelial and myoepithelial lin-
eage specific growth inhibitory effects, we identified several drugs that
induced dose-dependent alterations on the diversity of the sub-cell lin-
eages, resulting in unique differentiation-state distributions in residual cell
populations following treatment (Fig. 3A). Overall, the lineage specific
drug responses could be grouped into four main classes: drugs having a
cytotoxic effect on all the cells, drugs more potent on the KRT19+ popu-
lation, drugs more potent on the KRT14+ population and drugs increasing
growth of both two lineages (Supplement Fig. 5). Interestingly, drugs with
same therapeutic targets grouped within these response classes. For exam-
ple, inhibitors targeting the PI3K/mTOR pathway, dose-dependently
decreased viability of KRT14+ cells while KRT19+ cell were more resistant
(Fig. 3A). Conversely, inhibitors targeting the MAP-Kinase (MAPK) path-
way, including MEK and BRaf inhibitors, and HDAC inhibitors dis-
played higher efficacy on the KRT19+ cells in comparison to KRT14+
cells (Fig. 3A). To expand the grouping of drugs according to lineage selec-
tivity, we compared the change in the proportional amount of KRT19+ vs.
KRT14+ cells in the residual population following drug treatment using
the Shannon diversity index H0 metric. We calculated the change in the
overall diversity index (DH0) by comparing the residual population indices
to the H0 index of DMSO only control samples (Fig. 3B). Here several
other drugs were identified having a similar lineage specific effect as the
MEK and mTOR inhibitors. Drugs having a myoepithelial lineage selec-
tive effect included e.g. Niclosamide, Vinblastine and Docetaxel. The dif-
ferential growth inhibitory effects of these groups of drugs on the two cell
populations is shown in Fig. 3C displaying the GR dose response curves of
the two populations. The impact to the same drugs on the proportional
lineage diversity is shown in Fig. 3D as % change of the proportional cell
population size in comparison to DMSO controls. Strikingly, the MEK
inhibitors increased the proportional amount of KRT14+ cells up to 4-
fold similarly as Vinblastine, Raf inhibitor AZ628 and Calcitriol (Fig. 3D).
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Combination of pathway targeted therapeutics
To analyze pathway inhibition and target engagement of the identified
drug candidates, we performed a high-throughput reverse-phase-protein
array (RPPA) screen with the patient¨s cells [21]. In the RPPA analysis
the cells were exposed for 72 h to a collection of 58 drugs selected from
the initial ex vivo analysis in 5 doses with 2-fold dilutions starting from
5 mM (Supplement data 3). Nine markers; phospo-p70S6R, phospho-
AKT, phospho-ERK, phospho-4EBP1, phospho-EIF4G, phospho-
Chk1, Ki-67 and EMA (MUC1) were used as the assay readout (Supple-
ment Fig. 5A). Molecular pathway analysis of the downstream signaling
markers confirmed a strong correlation between the viability of the
EMC cells and the engagement of each of the targeted inhibitors on their
targets for the PI3K/AKT/mTOR, and the RAS/RAF/MEK pathways
(Supplement Fig. 5B). Drugs including MEK inhibitor selumetinib and
HDAC inhibitors effectively blocked downstream p-ERK1/2 signaling,
while mTOR, PI3K, AKT and CDK inhibitors had a marked dose depen-
dent reduction in downstream mTORC1/2 effectors p-AKT, p-S6RP and
p-4EBP1. CDK inhibition and WEE1 inhibitor AZD1775 resulted in sig-
nificant dose dependent induction of DNA damage marked by increased
yH2Ax positivity and downregulated p-Chk1 S345 (Supplement Fig. 5A).
Supported by the pathway inhibition analysis and the apparent differ-
ential sensitivity of the KRT19+ and the KRT14+ cells on MAPK/mTOR
pathway inhibition, we rationalized that combination of MEK and mTOR
inhibition should potentiate the overall therapeutic efficacy of the single
agents. We explored the effects of combining two of the highest-ranking
drugs with a divergent growth inhibitory effect; MEK inhibitor
AZD6244 (Selumetinib) and mTORC1/2 inhibitor AZD2014 (Vis-
tusertib). Patient cells were treated for 96 h with the two inhibitors in a
dose–response matrix to identify synergistic relationships of the two drugs
(Fig. 4A). At equal molar ratio of 1:1, the combination showed significant
additive effects (CI50 Combination index: 0.22) of reducing cell prolifer-
ation and increasing apoptosis resulting in a net reduction in cell numbers
of both lineages following 96 h of treatment (Fig. 4A & 4B). Analysis of
the synergy of the drug combinations with the other drug kept at a fixed
dose revealed higher synergistic behavior of AZD2014 in low doses when
Fig. 2. Ex vivo high content imaging drug screening. (A) Growth rate normalization of the dose responses was applied using aphidicolin as a cell growth
stalling control agent. In the ex vivo cell culture 70% of cells expressed KRT19 and 17% KRT14. The calculated cell doubling rate was measured for
all cells and KRT19/KRT14 positive cells separately. (B) A heatmap visualization of the GR value scored dose responses for all cells, KRT19+ cells and
KRT14+ cells. Shannon diversity index measurements were used to score divergent effects of the drugs to epithelial and myoepithelial cells. (C)
Correlations of the IC50 estimates of all the growth modulating drugs between all cells and KRT19+/KRT14+ cells and KRT19+ vs. KRT14+ cells. (D)
Correlation matrix of the GR dose response profiles of the most effective targeted agents identified by the drug screening between KRT19+ and KRT14+
cells. Pearson correlation value r indicated with the intensity of the color. Red positive correlation, blue negative correlation. (E) Scatter plot showing the
correlation of the lineage specific GR dose response correlations and the significance (log10p-val, Welch's t test).
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combined with AZD6244 than AZD6244 when combined with
AZD2014 (Fig. 4A). Scaled-up replicate experiments for analysis of the
target engagement and lineage inhibition of the combination was validated
with conventional immunoblot analysis (Fig. 4C). Specifically, the combi-
nation of AZD6244 and AZD2014 resulted in high efficacy inhibition of
the mTORC1 and S6 ribosomal protein suggesting the combination to
may overcome the negative feedback of mTORC1/S6 kinase1 feedback
loop described in several cancer models [22–24].
Ex vivo informed treatment
For EMC, there is no second-line treatment guidelines and no suitable
clinical trials existed for this tumor type. Therefore, patient was considered
for experimental therapeutic approaches informed by the ex vivo screening.
Based on the drug screening results, the patient¨s tumor cells were highly
sensitive in a differentiation state dependent manner to MEK and mTOR
inhibition. These results could also be associated with findings from the
whole exome sequencing of the tumor tissue. Key oncogenic aberrations
discovered in the patient tumor cells included mutations in ARID1B,
ATR (I774N), ERBB4 (V298G), HRAS (G13R), MAPK1 (AG7G),
PIK3R1 (RE461Q), PIK3R1 (L244*) and RPTOR (W1313G) (Supple-
ment data 1, Table 1).
Both HRAS and PIK3R1 mutations are associated based on in vitro
and in vivo evidence with increased sensitivity of cancer cells to MEK inhi-
bition [25,26]. Mutations in PI3KR1 gene coding for p85a, the regulatory
subunit of PI3K, may also convert sensitivity to targeted PI3K and down-
stream effector inhibition including AKT and mTOR [27]. Mutations of
RPTOR are associated with in vivo activity of mTOR inhibition and par-
tial response to inhibition of MEK [28]. Based on these and the ex vivo
results and after unsuccessful search of available clinical trials for
mTOR-MEK combination therapies, the patient was started on Everoli-
mus mTOR inhibitor therapy at a daily 10 mg dose adopted from renal
cell cancer indication. Clinical benefit from this therapy was apparent
already at the first control one month after initiation of therapy. Radio-
graphic examination indicated initially a 25% reduction of the diameter
of the largest metastatic disease lesions (Fig. 5). Further follow-up whole-
body CT scans showed that the disease remained stable for 11 months
under the Everolimus therapy. At the time of disease progression, a new
subcutaneous metastatic lesion appeared in right mid-axillary line. A
Fig. 3. Lineage specific drug responses. (A) Gallery views of the or screening samples for the drugs with the strongest divergent growth inhibitory effect
on the KRT19+ and KRT14+ EMC cells. KRT19 shown in red, KRT14 shown in green and DNA blue. Bars 100 mm. (B) Scatter plot showing the
correlation of the drug induced Shannon diversity index changes (DH¨) in the KRT19+ and KRT14+ cell populations. Drugs highlighted with red
increased the proportional amount of KRT19+ cells in the screen and drugs highlighted in green increased the proportional amount of KRT14+ cells in
the screen. (C) Comparison of the lineage specific GR dose response curves for the KRT19+ (red) and KRT14+ (green) populations. (D) Visualization of
the proportional changes of the KRT19+ and KRT14+ population sizes following exposure to the drugs in an increasing dose.
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new biopsy sample was retrieved from this lesion. Tumor cells from the
new lesion stained positive for HER2 without detection of amplification
of the HER2/ERBB2 gene with CISH. Based on results from the initial
ex vivo screen showing moderate response of the patient's tumor cells to
inhibition of EGFR/HER2 axis and high protein level HER2 staining, a
new treatment attempt was made using combination of trastuzumab–em-
Fig. 4. Drug combinations in EMC. (A) Dose–response matrix of percent of viability at increasing doses of AZD2014 (mTOR inhibitor) and AZD6244
(MEK inhibitor). The measured CI50 combination index of AZD2014 and AZD6244 was 0.22. Lower panel, comparison of growth inhibition dose
responses of AZD2014 and AZD6244 with fixed concentration of the other drug. (B) Immunofluorescent staining of EMC cells with KRT19 (red) and
KRT14 (green) following 96-h treatment with single agent AZD2014, AZD6244, combination of the two and control DMSO treated cells. Bar 50 mm.
C, EMC cells were treated with DMSO (), 1000 nmol/L AZD2015, 1000 nmol/L AZD6244, or the combination for 4, 24 and 72 h, and
phosphorylation (p) and total protein levels of indicated markers was assessed. GAPDH was assessed as a loading control.
Table 1. Key oncogenic aberrations discovered in the patient tumor cells.
Gene Effect Impact Codon_Change Exon AA_Change
ARID1B CODON_DELETION MODERATE caggcg/cag 1 QA456Q
ATR FRAME_SHIFT HIGH ata/aAta 10 I774N
CDK12 FRAME_SHIFT HIGH –/– 14 1443
ERBB4 NON_SYNONYMOUS_CODING MODERATE gTg/gGg 8 V298G
HRAS NON_SYNONYMOUS_CODING MODERATE Ggt/Cgt 2 G13R
MAPK1 CODON_CHANGE_PLUS_CODON_DELETION MODERATE gcgggc/ggc 1 AG7G
NANOG NON_SYNONYMOUS_CODING MODERATE Act/Cct 4 T281P
NANOG STOP_GAINED HIGH Caa/Taa 4 Q301*
NOTCH2 FRAME_SHIFT HIGH –/– 1 6
PIK3R1 CODON_CHANGE_PLUS_CODON_DELETION MODERATE cgagaa/caa 10 RE461Q
PIK3R1 STOP_GAINED HIGH tTa/tAa 5 L244*
RPTOR NON_SYNONYMOUS_CODING MODERATE Tgg/Ggg 33 W1313G
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tansine (Kadcyla) and Lapatinib. Patient reported that disease lesions were
less painful during the therapy; however, whole-body CT scans showed
unequivocal progression of the disease at multiple disease locations. At that
point, patient was switched to best palliative care and received radiation
therapy to painful disease lesions. She succumbed to disease shortly after
stopping of active treatment.
Conclusions
We report here the first described ex vivo study and clinical use of drug
efficacy testing in epithelial myoepithelial carcinoma. In an effort to model
therapeutic options for a patient with an aggressive metastatic EMC, we
performed a high content image-based ex vivo drug screening using tumor
cells freshly isolated from a lung metastasis coarse needle biopsy. The anal-
ysis yielded dose and target dependent cytotoxic profiles for tens of drugs
which could be linked to genetic features of the patient's cancer cells.
Moreover, the analysis identified significant differential drug sensitivity
between the sub-cell lineages composing the tumor tissue highlighting
the importance of lineage heterogeneity of tumors contributing to therapy
sensitivity. Especially targeted therapeutics could be linked with differen-
tial pathway dependency in the epithelial and myoepithelial tumor cells.
These included a mTOR inhibitors, MEK inhibitors, HDAC inhibitors
and topoisomerase inhibitors. The lineage specific interrogation of drug
induced growth inhibition also highlighted the importance of implement-
ing growth rate corrected dose response measurements, a feature largely
neglected in the drug screening approaches published to date.
In summary, by interrogating patient-derived cells in this ex vivo study
we identify mTOR and MEK inhibitors as potential therapeutic options
that could be considered as alternative treatment regimens for patients
with a metastatic epithelial myoepithelial carcinoma. These results also
suggest that the lineage heterogeneity in epithelial myoepithelial salivary
gland cancer can present a partial outlet to targeted therapy and that lin-
eage heterogeneity could be considered as a predictive biomarker when
selecting among pathway targeted treatment options that are known to
display lineage selectivity also in other cancers [29].
Declarations of interest
Dr Juha K. Rantala is the founder and CEO of Misvik Biology Ltd.
The authors declare no potential conflicts of interest.
Acknowledgements
We would like to thank the patient and the family with whom this study is
connected and the personnel of the Central Finland Health Care District,
JyvÌskylÌ Medical Centre Oncology Department. The ODM-207 bro-
modomain inhibitor was provided to the study kindly by Dr. Anu Moila-
nen (Orion, Turku, Finland).
Funding
This work has been supported in part by AZ-SLL-KI open innovation
grant #18122013. The funding body had no input in the design of the
study, collection, analysis or interpretation of the data.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.neo.2020.06.007.
References
1. Donath K, Seifert G, Schmitz R. Diagnosis and ultrastructure of the tubular
carcinoma of salivary gland ducts: epithelial-myoepithelial carcinoma of the
intercalated ducts [in German]. Virchows Arch A Pathol Pathol Anat
1972;356:16–31.
2. VÄzquez A, Patel TD, D'Aguillo CM, Abdou RY, Farver W, Baredes S, et al.
Epithelial-myoepithelial carcinoma of the salivary glands: an analysis of 246
cases. Otolaryngol Head Neck Surg 2015;153(4):569–74.
3. Senis-Segarra L, Sahuquillo-Arce E, Davo R, Hamad-Arcis P, Floria-Garcia
MC, Baquero MC. Salivary gland epithelial-myoepithelial carcinoma:
behaviour, diagnosis and treatment. Med Oral 2002;7:391–5.
Fig. 5. Clinical response to Everolimus (mTOR inhibitor) therapy. Following four weeks of treatment with 10 mg/day Everolimus the intrapulmonary
metastasis lesions showed 25% reduction in diameter.
Neoplasia Vol. 22, No. 9, 2020 Ex vivo assessment of targeted therapies in a rare metastatic R. MÌkelÌ et al. 397
4. Seethala RR, Barnes EL, Hunt JL. Epithelial-myoepithelial carcinoma: a review
of the clinicopathologic spectrum and immunophenotypic characteristics in 61
tumors of the salivary glands and upper aerodigestive tract. Am J Surg Pathol
2007;31:44–57.
5. Shinozaki A, Nagao T, Endo H, Kato N, Hirokawa M, Mizobuchi K, et al.
Sebaceous epithelial-myoepithelial carcinoma of the salivary gland:
clinicopathologic and immunohistochemical analysis of 6 cases of a new
histologic variant. Am J Surg Pathol 2008;32(6):913–23.
6. Venook AP, Tseng A, Meyers FJ, Silverberg I, Boles R, Fu KK, Jacobs CD.
Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland
malignancies: a pilot study of the Northern California Oncology Group. J Clin
Oncol 1987;5:951–5.
7. Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S,
Bumma C. Phase II randomized trial comparing vinorelbine versus vinorelbine
plus cisplatin in patients with recurrent salivary gland malignancies. Cancer
(Phila.) 2001;91:541–7.
8. Jennings T, Li Y, Pinto H, Kies M, Mansour E, Foratsiere A. Phase II trial of
paclitaxel in advanced or metastatic salivary gland malignancies: an Eastern
Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 2001;20:236a.
9. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in
cancer. Cancer Res 2012;72(10):2457–67.
10. Cros JF, Blons H, Sbidian E, Tartour E, Hans S, Brasnu D, et al. Expression
and prognostic significance of directed therapy targets and mutational analysis
of the EGFR pathway in malignant salivary gland tumors. J Clin Oncol
2012;30:5554.
11. Chiosea SI, Miller M, Seethala RR. HRAS mutations in epithelial-
myoepithelial carcinoma. Head and Neck Pathol 2014;8:146–50.
12. Kettunen K, BostrÎm PJ, Lamminen T, et al. Personalized drug sensitivity
screening for bladder cancer using conditionally reprogrammed patient-derived
cells. Eur Urol 2019;76(4):430–4.
13. Lehtomaki KI, Lahtinen LI, Rintanen N, et al. Clonal evolution of MEK/
MAPK pathway activating mutations in a metastatic colorectal cancer case.
Anticancer Res 2019;39(11):5867–77.
14. Arjonen A, MÌkelÌ R, HÌrmÌ V, et al. Image-based ex vivo drug screen to assess
targeted therapies in recurrent thymoma. Lung Cancer 2020;145:27–32.
15. Billingham L, Malottki K, Steven N. Research methods to change clinical
practice for patients with rare cancers. Lancet Oncol 2016;17:e70–80.
16. Shannon CE, Weaver W. The Mathematical Theory of
Communication. University of Illinois Press; 1963.
17. Chou TC. Drug combination studies and their synergy quantification using the
Chou-Talalay method. Cancer Res 2010;70:440–6.
18. Labarge MA, Garbe JC. Stampfer MR. Processing of human reduction
mammoplasty and mastectomy tissues for cell culture. J Vis Exp 2013(71).
19. Hafner M, Heiser LM, Williams EH, Niepel M, Wang NJ, Korkola JE, et al.
Quantification of sensitivity and resistance of breast cancer cell lines to anti-
cancer drugs using GR metrics. Sci Data 2017;4 170166.
20. Neumann B, Walter T, HÅrichÅ JK, Bulkescher J, Erfle H, Conrad C, et al.
Phenotypic profiling of the human genome by time-lapse microscopy reveals
cell division genes. Nature 2010;464(7289):721–7.
21. Gujral TS, Karp RL, Finski A, Chan M, Schwartz PE, MacBeath G, Sorger P.
Profiling phospho-signaling networks in breast cancer using reverse-phase
protein arrays. Oncogene 2013;32:3470–6.
22. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. NVPBEZ235, a
dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth
of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022–30.
23. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, et al. Dual inhibition
of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic
strategy for acute myeloid leukemia. Clin Cancer Res 2010;16:5424–35.
24. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski
JS, et al. Dynamic reprogramming of the kinome in response to targeted MEK
inhibition in triple-negative breast. Cancer Cell 2012;149:307–21.
25. Cheung LW, Yu S, Zhang D, Li J, Ng PK, Panupinthu N, et al. Naturally
occurring neomorphic PIK3R1 mutations activate the MAPK pathway,
dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell
2014;26(4):479–94.
26. Kiessling MK, Curioni-Fontecedro A, Samaras P, Atrott K, Cosin-Roger J,
Lang S, et al. Mutant HRAS as novel target for MEK and mTOR inhibitors.
Oncotarget 2015;6(39):42183–96.
27. Cheung LW, Mills GB. Targeting therapeutic liabilities engendered by
PIK3R1 mutations for cancer treatment. Pharmacogenomics 2016;3:297–307.
28. Dela Cruz FS, Diolaiti D, Turk AT, Rainey AR, Ambesi-Impiombato A,
Andrews SJ, et al. A case study of an integrative genomic and experimental
therapeutic approach for rare tumors: identification of vulnerabilities in a
pediatric poorly differentiated carcinoma. Genome Med 2016;8(1):116.
29. Risom T, Langer EM, Chapman MP, Rantala J, Fields AJ, Boniface C, et al.
Differentiation-state plasticity is a targetable resistance mechanism in basal-like
breast cancer. Nat Commun 2018;9(1):3815.
398 Ex vivo assessment of targeted therapies in a rare metastatic R. MÌkelÌ et al. Neoplasia Vol. 22, No. 9, 2020
